Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors

NCT07030257 is registered in ClinicalTrials.gov with Tasca Therapeutics as lead sponsor.

NCT NCT07030257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07030257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors
Lead sponsor
Tasca Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 27, 2025
Completion date
February 28, 2029
Enrollment
150 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, colorectal carcinoma, head and neck (hnscc), non-small cell lung cancer, pancreatic cancer, advanced or metastatic, small cell lung cancer ( sclc ), solid tumor malignancies